Cataract News

News

Delayed capsulotomy much preferable over early procedure to prevent AEs

20230518110000

Ocular hypertension (OHT) and macular edema (ME) are the most common and relevant adverse events (AEs) following neodymium:yttrium-aluminum-garnet posterior capsulotomy (Nd:YAG-caps), reports a study. These AEs normally occur within 3 months after the procedure, which stresses the need for a close follow-up during this period or a delayed capsulotomy.

Novel topical dexamethasone formulation reduces inflammation, pain after cataract surgery

20221217080000

OCS-01, a topical dexamethasone 1.5% in a novel formulation, appears to be safe and effective in the management of inflammation and pain following cataract surgery, a study has found.

Glucose-lowering medications protect against glaucoma, AMD

20220729080000

While diabetes is a risk factor for cataract, glucose-lowering medications appear to have a protective effect on the risks of open-angle glaucoma (OAG) and age-related macular degeneration (AMD), as shown in a study.

Does cataract surgery raise the risk of developing late AMD?

20220414120000

A recent study has found that cataract surgery does not contribute to a higher risk of developing late age-related macular degeneration (AMD) among Age-Related Eye Disease Study 2 (AREDS2) participants with up to 10 years of follow-up.

NSAIDs: suitable prophylaxis after cataract surgery?

Audrey Abella, 20210928100000

The addition of corticosteroids (ie, prednisolone) to NSAID eyedrops (ie, ketorolac) did not provide additional benefit relative to ketorolac alone or dropless surgery using a sub-Tenon capsule depot as an anti-inflammatory prophylactic regimen to prevent postoperative central macular thickening following uncomplicated cataract surgery, a Danish study suggests.

Light, moderate drinking may be good for eyes

Jairia Dela Cruz, 20210216140000

Light to moderate alcohol consumption has the potential to lower the risk of cataract requiring surgery, and the protection is especially pronounced among wine drinkers, as shown in a study.

Long-term hormone therapy may increase cataract risk in women with T2D

20200323060000

Use of hormone therapy in the long term potentially carries a heightened risk of cataract in postmenopausal women with type 2 diabetes (T2D), a study reports.

Certain blood pressure-, lipid-, glucose-lowering meds may affect cortical cataract risk in Asians

Jairia Dela Cruz, 20190802130000

Asians who use angiotensin-converting enzyme inhibitors, fibrates, alpha-glucosidase inhibitors or insulin are likely to have cortical cataract, independent of the presence of hypertension, hyperlipidaemia or diabetes, according to data from the Singapore Epidemiology of Eye Diseases (SEED) study.

One in 10 undergoes cataract surgery; diabetes, myopia tied to cataract prevalence

Jairia Dela Cruz, 20181206110000

One in 10 Malay, Indian and Chinese Singaporeans aged ≥40 years undergoes cataract surgery in at least one eye over 6 years, according to data from the Singapore Epidemiology of Eye Diseases (SEED) Study. Diabetes and myopia are modifiable risk factors for cataract prevalence.

Increased breastfeeding frequency, duration protective against cataract

20180620060000

Parous women who are breastfeeding more children and have been doing so in the long-term appear to have a lower risk of developing cortical cataract, a study reports.

Opacity usually appears later in the development of cataract.

Diagnosing cataract prior to detection of opacity

June Chiang, Ph.D, 26 May 2022

A new algorithm objectively determines when intraocular lens implant (IOL) surgery should be performed, regardless of how the opacity looks to the surgeon.

Product Highlight - Idacio

13 Sep 2022

Adalimumab soln for inj 40 mg/0.8 mL

No increased ophthalmic risk with roxadustat treatment in DD CKD-related anaemia

Roshini Claire Anthony, 28 Jun 2020

Roxadustat treatment for anaemia in patients with dialysis-dependent chronic kidney disease (DD CKD) does not come with an increased risk of ophthalmic abnormalities, according to a phase III trial conducted in Japan.